Our Partners

Advancing pharmaceutical innovation through collaborative synergy

Partnerships are at the heart of OEP’s mission to bring patients innovative, high-quality products.

We don’t just help develop and sell products. We create synergy. By focusing on building relationships, and maintaining nimble, customer-centric operations, we produce an end result greater than the sum of its parts.

Read our partnership profiles below to discover how an alliance with OEP drives mutual growth.



  • Cel-Sci
  • chiesi
  • Debiopharm-1
  • Untitled design (12)
  • Pierre Fabre-1
  • Plethora
  • Recordati
  • Second Sight
  • Supernus
  • New Teva logo
  • Untitled design (10)
  • Untitled design (4)
  • kissei 5
  • nanocarrier
  • Untitled design (2)
  • summit
  • Untitled design (7)
  • Untitled design (8)
  • logo
  • PAI
  • teva logo official
  • Tide

Partnership Profiles

Out-licensing of Vancomycin capsules with PAI 

In-licensing of Multikine® cancer drug with CEL-SCI 

Co-development of 505(b)(2) ADHD Drug with DURECT 

In-licensing of CNS Drug with Supernus Pharmaceuticals  

Hear From Our Partners

“We congratulate OEP on the approval and recent commercial launch of Methydur, which will offer an alternative treatment for patients suffering from ADHD in Taiwan. We are pleased to see this first marketing approval for a product utilizing the ORADUR technology." 

By James E. Brown, President and CEO of DURECT Corporation  

“OEP has been a valued partner in CEL-SCI’s mission to help patients beat cancer by developing innovative immunotherapies. OEP has been meticulous in their clinical trial management of Multikine in Taiwan, and we are pleased to be able to leverage their extensive commercialization network in Asia.”.

By Geert R. Kersten, Director and CEO, CEL-SCI

“As a leader in high-quality generic pharmaceuticals for the North American market, PAI is delighted to enhance our consumer offerings with OEP’s Vancomycin product.”

By Kurt Orlofski, CEO, Pharmaceutical Associates, Inc.